Live feed08:05:00·21mPRReleasevia QuantisnowIMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of PlanByQuantisnow·Wall Street's wire, on your screen.IMNN· Imunon Inc.Health Care
